Publications in collaboration with researchers from University of Oslo (25)

2024

  1. Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease

    Computers in Biology and Medicine, Vol. 176

2023

  1. Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology

    Alzheimer's and Dementia, Vol. 19, Núm. 3, pp. 807-820

  2. Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease

    Alzheimer's and Dementia, Vol. 19, Núm. 8, pp. 3350-3364

  3. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

    Genome Medicine, Vol. 15, Núm. 1

  4. Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits

    Alzheimer's and Dementia, Vol. 19, Núm. 6, pp. 2317-2331

2022

  1. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease

    Molecular neurodegeneration, Vol. 17, Núm. 1, pp. 27

  2. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (Molecular Neurodegeneration, (2022), 17, 1, (27), 10.1186/s13024-022-00521-3)

    Molecular Neurodegeneration

  3. Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 14, Núm. 1

  4. Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset

    Frontiers in Aging Neuroscience, Vol. 14

  5. Predicting AT(N) pathologies in Alzheimer’s disease from blood-based proteomic data using neural networks

    Frontiers in Aging Neuroscience, Vol. 14

  6. Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation

    Molecular Psychiatry, Vol. 27, Núm. 4, pp. 1990-1999

2021

  1. Csf proteomic alzheimer’s disease-predictive subtypes in cognitively intact amyloid negative individuals

    Proteomes, Vol. 9, Núm. 3

  2. Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies

    Frontiers in Aging Neuroscience, Vol. 13

  3. Replication study of plasma proteins relating to Alzheimer's pathology

    Alzheimer's and Dementia, Vol. 17, Núm. 9, pp. 1452-1464

  4. Sex-specific metabolic pathways were associated with alzheimer’s disease (Ad) endophenotypes in the european medical information framework for ad multimodal biomarker discovery cohort

    Biomedicines, Vol. 9, Núm. 11

  5. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels

    Alzheimer's and Dementia, Vol. 17, Núm. 10, pp. 1628-1640

2020

  1. APOE ϵ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease

    Alzheimer's Research and Therapy, Vol. 12, Núm. 1

  2. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology

    Journal of Alzheimer's Disease, Vol. 77, Núm. 3, pp. 1353-1368

  3. Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset

    Translational Psychiatry, Vol. 10, Núm. 1

  4. Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort

    Journal of Alzheimer's Disease, Vol. 74, Núm. 1, pp. 213-225